Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Volitionrx (VNRX) Research & Development (2019 - 2025)

Volitionrx's Research & Development history spans 9 years, with the latest figure at $2.5 million for Q4 2025.

  • For Q4 2025, Research & Development fell 4.61% year-over-year to $2.5 million; the TTM value through Dec 2025 reached $10.1 million, down 30.02%, while the annual FY2025 figure was $10.1 million, 30.02% down from the prior year.
  • Research & Development reached $2.5 million in Q4 2025 per VNRX's latest filing, up from $2.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $5.5 million in Q2 2023 to a low of $2.3 million in Q3 2025.
  • Average Research & Development over 5 years is $3.6 million, with a median of $3.6 million recorded in 2021.
  • Peak YoY movement for Research & Development: skyrocketed 66.23% in 2023, then tumbled 43.68% in 2025.
  • A 5-year view of Research & Development shows it stood at $3.3 million in 2021, then increased by 26.04% to $4.1 million in 2022, then increased by 10.02% to $4.5 million in 2023, then crashed by 43.06% to $2.6 million in 2024, then decreased by 4.61% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for VNRX's Research & Development are $2.5 million (Q4 2025), $2.3 million (Q3 2025), and $2.7 million (Q2 2025).